These compelling outcomes have now provided confidence for the company to evaluate the further progression of ZLT-L-007 into formal FDA clinical trials.“The results align perfectly with our strategy of generating scientifically rigorous and clinically validated data for our patent-protected proprietary cannabinoid-based drugs,” said Zelira CEO, Dr Oludare Odumosu.Additional insights from the full study will be reported, as they become available, during FY 23-23.
An extract from the Australian
Ann: Zeliras diabetic nerve pain drug outperforms Lyrica, page-75
-
- There are more pages in this discussion • 143 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ZLD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
75.5¢ |
Change
0.150(24.8%) |
Mkt cap ! $8.567M | |||
| Open | High | Low | Value | Volume |
| 60.0¢ | 75.5¢ | 60.0¢ | $16.04K | 23.72K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2000 | 75.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 78.5¢ | 1634 | 2 |
View Market Depth
| Last trade - 15.59pm 12/07/2024 (20 minute delay) ? |
| ZLD (ASX) Chart |